JPH09502167A - 新規な幹細胞マーカー - Google Patents

新規な幹細胞マーカー

Info

Publication number: JPH09502167A
Authority: JP; Japan
Prior art keywords: cells; hca; further characterized; composition; cell
Prior art date: 1993-07-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP7505995A

Other languages

English (en)

Japanese (ja)

Inventor

ポール，ブルノ

ウチダ，ノブコ

Original Assignee

システミックス，インコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-29

Filing date

1994-07-29

Publication date

1997-03-04

1994-07-29 Application filed by システミックス，インコーポレイテッド filed Critical システミックス，インコーポレイテッド

1997-03-04 Publication of JPH09502167A publication Critical patent/JPH09502167A/ja

Status Pending legal-status Critical Current

Links

210000000130 stem cell Anatomy 0.000 title claims abstract description 96
239000002771 cell marker Substances 0.000 title abstract description 4
210000004027 cell Anatomy 0.000 claims abstract description 235
210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 47
238000000034 method Methods 0.000 claims abstract description 46
239000000203 mixture Substances 0.000 claims description 46
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 40
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 40
238000000926 separation method Methods 0.000 claims description 20
101150052863 THY1 gene Proteins 0.000 claims description 14
239000003550 marker Substances 0.000 claims description 12
239000007850 fluorescent dye Substances 0.000 claims description 6
230000002062 proliferating effect Effects 0.000 abstract 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 36
238000010186 staining Methods 0.000 description 35
108090000623 proteins and genes Proteins 0.000 description 17
238000004458 analytical method Methods 0.000 description 16
210000003719 b-lymphocyte Anatomy 0.000 description 15
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 14
210000001185 bone marrow Anatomy 0.000 description 13
210000002536 stromal cell Anatomy 0.000 description 13
210000001744 T-lymphocyte Anatomy 0.000 description 12
230000001605 fetal effect Effects 0.000 description 11
230000003394 haemopoietic effect Effects 0.000 description 11
239000002609 medium Substances 0.000 description 11
210000000988 bone and bone Anatomy 0.000 description 10
238000002955 isolation Methods 0.000 description 10
238000004519 manufacturing process Methods 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
108091003079 Bovine Serum Albumin Proteins 0.000 description 9
239000012894 fetal calf serum Substances 0.000 description 9
239000000427 antigen Substances 0.000 description 8
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
210000003743 erythrocyte Anatomy 0.000 description 8
230000007774 longterm Effects 0.000 description 8
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
238000001514 detection method Methods 0.000 description 7
230000004069 differentiation Effects 0.000 description 7
229960000890 hydrocortisone Drugs 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000003102 growth factor Substances 0.000 description 6
210000000066 myeloid cell Anatomy 0.000 description 6
210000005259 peripheral blood Anatomy 0.000 description 6
239000011886 peripheral blood Substances 0.000 description 6
210000001541 thymus gland Anatomy 0.000 description 6
241000287828 Gallus gallus Species 0.000 description 5
108090000288 Glycoproteins Proteins 0.000 description 5
102000003886 Glycoproteins Human genes 0.000 description 5
230000027455 binding Effects 0.000 description 5
210000002798 bone marrow cell Anatomy 0.000 description 5
235000013330 chicken meat Nutrition 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
241000699670 Mus sp. Species 0.000 description 4
238000003556 assay Methods 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
230000007812 deficiency Effects 0.000 description 4
239000000975 dye Substances 0.000 description 4
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
239000012634 fragment Substances 0.000 description 4
230000012010 growth Effects 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
230000008929 regeneration Effects 0.000 description 4
238000011069 regeneration method Methods 0.000 description 4
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 4
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
102000053642 Catalytic RNA Human genes 0.000 description 3
108090000994 Catalytic RNA Proteins 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
108090001005 Interleukin-6 Proteins 0.000 description 3
102000004058 Leukemia inhibitory factor Human genes 0.000 description 3
108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
108090000028 Neprilysin Proteins 0.000 description 3
102000003729 Neprilysin Human genes 0.000 description 3
108010004729 Phycoerythrin Proteins 0.000 description 3
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
238000000149 argon plasma sintering Methods 0.000 description 3
239000011324 bead Substances 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
210000000601 blood cell Anatomy 0.000 description 3
230000024245 cell differentiation Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000003501 co-culture Methods 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
230000009395 genetic defect Effects 0.000 description 3
210000000777 hematopoietic system Anatomy 0.000 description 3
238000002372 labelling Methods 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
108091092562 ribozyme Proteins 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
102000028180 Glycophorins Human genes 0.000 description 2
108091005250 Glycophorins Proteins 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
108090000144 Human Proteins Proteins 0.000 description 2
102000003839 Human Proteins Human genes 0.000 description 2
102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
102000018120 Recombinases Human genes 0.000 description 2
108010091086 Recombinases Proteins 0.000 description 2
108091008874 T cell receptors Proteins 0.000 description 2
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
239000003636 conditioned culture medium Substances 0.000 description 2
238000012258 culturing Methods 0.000 description 2
230000008021 deposition Effects 0.000 description 2
239000010432 diamond Substances 0.000 description 2
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
230000011132 hemopoiesis Effects 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
230000035800 maturation Effects 0.000 description 2
210000003593 megakaryocyte Anatomy 0.000 description 2
230000002438 mitochondrial effect Effects 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
230000036457 multidrug resistance Effects 0.000 description 2
210000003643 myeloid progenitor cell Anatomy 0.000 description 2
210000005170 neoplastic cell Anatomy 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
244000052769 pathogen Species 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
230000005855 radiation Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000035899 viability Effects 0.000 description 2
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
241000905957 Channa melasoma Species 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
240000006519 Desmodium elegans Species 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
229930190887 Leptomycin Natural products 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101100293261 Mus musculus Naa15 gene Proteins 0.000 description 1
101100189590 Mus musculus Pde6b gene Proteins 0.000 description 1
101150082943 NAT1 gene Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000036848 Porzana carolina Species 0.000 description 1
241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
108010004469 allophycocyanin Proteins 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
208000005980 beta thalassemia Diseases 0.000 description 1
210000002960 bfu-e Anatomy 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000002449 bone cell Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000011748 cell maturation Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
238000007821 culture assay Methods 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
239000003145 cytotoxic factor Substances 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
210000003013 erythroid precursor cell Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
210000001981 hip bone Anatomy 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
239000002523 lectin Substances 0.000 description 1
YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical compound OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
238000007885 magnetic separation Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000004091 panning Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000009013 pigment accumulation Effects 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
230000002265 prevention Effects 0.000 description 1
210000001948 pro-b lymphocyte Anatomy 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
102000009099 rhoA GTP Binding Protein Human genes 0.000 description 1
108010087917 rhoA GTP Binding Protein Proteins 0.000 description 1
MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000009738 saturating Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
210000002303 tibia Anatomy 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
210000001325 yolk sac Anatomy 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1394—Bone marrow stromal cells; whole marrow

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Developmental Biology & Embryology (AREA)
Immunology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Cell Biology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Investigating Or Analysing Biological Materials (AREA)

JP7505995A 1993-07-29 1994-07-29 新規な幹細胞マーカー Pending JPH09502167A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10063393A	1993-07-29	1993-07-29
US08/100,633		1993-07-29
PCT/US1994/008574 WO1995003693A1 (en)	1993-07-29	1994-07-29	Novel stem cell marker

Publications (1)

Publication Number	Publication Date
JPH09502167A true JPH09502167A (ja)	1997-03-04

Family

ID=22280745

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP7505995A Pending JPH09502167A (ja)	1993-07-29	1994-07-29	新規な幹細胞マーカー

Country Status (5)

Country	Link
EP (1)	EP0711111A4 (de)
JP (1)	JPH09502167A (de)
AU (1)	AU7476694A (de)
CA (1)	CA2168348A1 (de)
WO (1)	WO1995003693A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08157499A (ja) *	1994-12-06	1996-06-18	Systemix Inc	新規な幹細胞マーカータンパク質をコードするヌクレオチド配列、該タンパク質のアミノ酸配列、該タンパク質の発現方法、単離したタンパク質の組成物、および該タンパク質に特異的な抗体
WO1996040875A1 (en) *	1995-06-07	1996-12-19	Novartis Ag	Methods for obtaining compositions enriched for hematopoietic stem cells and antibodies for use therein
AU6223196A (en) *	1995-06-07	1996-12-30	Novartis Ag	Methods for obtaining compositions enriched for hematopoietic stem cells and antibodies for use therein
US5728581A (en) *	1995-06-07	1998-03-17	Systemix, Inc.	Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
US6060052A (en) *	1995-10-30	2000-05-09	Systemix, Inc.	Methods for use of Mpl ligands with primitive human hematopoietic stem cells
AU3440797A (en) *	1996-07-01	1998-01-21	Novartis Ag	Process of obtaining compositions enriched for hematopoietic stem cells and antibodies for use therein
WO1998021334A2 (en) *	1996-11-13	1998-05-22	Morphogenesis, Inc.	Antibody mg1 recognizing a small subset of human hematopoietic cells
WO2004046312A2 (en)	2002-11-15	2004-06-03	The Board Of Trustees Of The University Of Illinois	Methods for in vitro expansion of hematopoietic stem cells
US8609411B2 (en)	2007-05-04	2013-12-17	Whitehead Institute For Biomedical Research	Ex vivo expansion of human hematopoietic stem cells
WO2011159684A2 (en)	2010-06-15	2011-12-22	Cellular Dynamics International, Inc.	Generation of induced pluripotent stem cells from small volumes of peripheral blood

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4714680B1 (en) *	1984-02-06	1995-06-27	Univ Johns Hopkins	Human stem cells
US5061620A (en) *	1990-03-30	1991-10-29	Systemix, Inc.	Human hematopoietic stem cell
WO1993025216A1 (en) *	1992-06-08	1993-12-23	Becton, Dickinson And Company	Human primitive stem cells

1994
- 1994-07-29 AU AU74766/94A patent/AU7476694A/en not_active Abandoned
- 1994-07-29 WO PCT/US1994/008574 patent/WO1995003693A1/en not_active Ceased
- 1994-07-29 EP EP94924518A patent/EP0711111A4/de not_active Withdrawn
- 1994-07-29 CA CA 2168348 patent/CA2168348A1/en not_active Abandoned
- 1994-07-29 JP JP7505995A patent/JPH09502167A/ja active Pending

Also Published As

Publication number	Publication date
EP0711111A4 (de)	1997-09-24
AU7476694A (en)	1995-02-28
EP0711111A1 (de)	1996-05-15
WO1995003693A1 (en)	1995-02-09
CA2168348A1 (en)	1995-02-09

Publication	Publication Date	Title
US5681559A (en)	1997-10-28	Method for producing a highly enriched population of hematopoietic stem cells
JP3779323B2 (ja)	2006-05-24	造血幹細胞に富む組成物を得る方法、それ由来の組成物および使用法
JP3160600B2 (ja)	2001-04-25	ヒト造血幹細胞
US5814440A (en)	1998-09-29	Methods of obtaining compositions enriched for hematopoietic stem cells, antibodies for use therein, compositions derived therefrom and methods of use thereof
Barcena et al.	1993	Phenotypic and functional analysis of T-cell precursors in the human fetal liver and thymus: CD7 expression in the early stages of T-and myeloid-cell development
JP3070865B2 (ja)	2000-07-31	ヒトプロジェニター細胞のサブセット
WO1996015228A1 (en)	1996-05-23	Method of purifying a population of cells enriched for hematopoietic stem cells
JPH09502167A (ja)	1997-03-04	新規な幹細胞マーカー
JP3957746B2 (ja)	2007-08-15	骨髄始原細胞および／またはリンパ系始原細胞について富化される細胞集団、ならびに製造方法および使用方法
AU8014694A (en)	1995-05-01	Methods for analysis of human stem cells
WO1994008039A1 (en)	1994-04-14	Method of enrichment for human hematopoietic stem cells using c-kit
WO1996040874A1 (en)	1996-12-19	Methods for obtaining compositions enriched for hematopoietic stem cells and antibodies for use therein
Larsson	1991	An" in vitro" analysis of murine thymocyte-stromal cell interactions
HK1059632A (en)	2004-07-09	Human hematopoietic stem cell